Krazati (adagrasib) - BMS
Lumakras (sotorasib) - Amgen
Computational identification and characterization of high-risk human KRAS nsSNPs: Impacting structure, ligand binding, and cancer prognosis. (PubMed, J Genet Eng Biotechnol) - Sep 17, 2026 - "Docking and simulation analyses showed that the Y71D and M72K nsSNPs reduced binding affinity and stability with ligand sotorasib (CID: 137278711) compared to wild-type KRAS, whereas both high-risk nsSNPs exhibited enhanced binding and stability with ligand adagrasib (CID: 138611145), indicating mutation-dependent ligand interactions. Cancer susceptibilities analyses indicated both Y71D and M72K may promote cancer prognosis. These results highlight Y71D and M72K as high-risk KRAS nsSNPs affecting structural stability, ligand interactions, and cancer prognosis, providing a framework for mutation-specific therapeutic strategies and supporting further experimental validation in precision oncology." 
Journal • Oncology • Solid Tumor • KRAS
http://www.ncbi.nlm.nih.gov/pubmed/42749446
 
Abu Zaffar Shibly; Afia Khandaker; Juthi Adhikari; Md Mainuddin Hossain; Md Zakiul Islam Zaki; Sabbir Ahmed
 
Sep 17, 2026
 
Prev Next